were predominantly men (68%), with the mean age of 68 ±11 years; 25% of the patients had de novo AHF and 57% had ischemic heart failure. The baseline clinical and laboratory characteristics of the study population are presented in TAbLE 1.
Every patient underwent standard clinical evaluation and transthoracic echocardiography with the measurements of the left ventricular ejection fraction (LVEF, Simpson method) and the right and left ventricular end-diastolic dimensions (RVEDD, LVEDD).
Patients were treated in accordance with the recommendations of the European Society of Cardiology. 11 The study protocol was approved by the local ethics committee, and the study was conducted in accordance with the Helsinki Declaration.
Laboratory measurements On admission, the following laboratory parameters were assessed in all patients using standard methods: 1) LFTs: AST, ALT, bilirubin, and albumin; in order to assess the prevalence of liver dysfunction we defined abnormal LFTs as the values above the upper normal limit for AST, ALT, bilirubin (38 IU/l, 35 IU/l, and 1.3 mg/dl, respectively) or below the lower normal limit for albumin (3.8 mg/dl); additionally, we defined a marked elevation of AST and ALT as exceeding 3 times the upper normal limit; 2) blood count: hemoglobin, leukocytes, platelets; 3) renal function: creatinine and blood urea nitrogen (BUN); 4) electrolytes: sodium (NA + ), potassium (K + ); 4) peripheral blood gases: pH, sO 2 , pCO 2 , serum osmolarity, lactate; 5) plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) by an immunoenzymatic method (Siemens, Marburg, Germany); 6) cardiac troponin I (TnI) by an immunoenzymatic method (single Dimension RxLMax, Siemens).
hemodynamic assessment In patients who required hemodynamic monitoring on the basis of clinical evaluation, pulmonary artery catheterization using the Swan-Ganz catheter was performed. Hemodynamic variables obtained during catheterization included: heart rate, blood pressure (systolic and diastolic), right atrial pressure (RAP), pulmonary artery pressure (PAP) (systolic, diastolic, mean), pulmonary capillary wedge pressure (PCWP), cardiac output (thermodilution method). Each invasive assessment included from 3 to 5 separate injections of cold saline (10 ml), and the cardiac output was calculated as the mean value of all injections. The cardiac index (CI) was determined as the cardiac output divided by the body surface area.
Clinical follow-up Data on survival was obtained directly from patients or their relatives (telephone contact), from the heart failure clinic database, or from the hospital system. No patient was lost to follow-up. The primary endpoint was all-cause death at 180 days. The length of follow-up of survivors and patients in whom the events occurred after 180 days were censored at 180 days.
We also aimed to establish potential determinants of abnormal LFTs and their impact on the patient's outcome.
PATIENTs ANd mEThOds study population
We performed a retrospective analysis of all patients who were hospitalized at the Centre of Heart Diseases, 4th Military Hospital, Wrocław, Poland, with primary diagnosis of AHF between January 2009 and October 2010, in whom the following LFTs were available on admission: serum bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), and albumin. Patients with known liver disease or with clinical diagnosis of acute coronary syndrome on admission were excluded from the analysis.
During recruitment, there were 242 hospitalized patients with the diagnosis of AHF, of whom 189 (78%) had all LFTs available at baseline and this group constituted the study population. They Compared with patients with normal albumin, patients with low albumin had ischemic etiology of heart failure less often, lower Na + , and higher NT-proBNP concentration (all P <0.05) (TAbLE 2).
Associations of abnormal liver function tests with other variables A multivariate regression model revealed that the following variables independently predicted abnormal LFTs (TAbLE 3): high hemoglobin and NT-proBNP levels for AST; high hemoglobin, bilirubin, and NT-proBNP levels for ALT; high hemoglobin, low sodium levels, and dilated RVEDD for bilirubin; and high NT-proBNP levels for albumin (all P <0.05).
Effect of liver dysfunction on mortality During 180-day follow-up, there were 40 deaths (21%). In a univariate Cox model, among abnormal LFTs, only low albumin and markedly elevated transaminases affected prognosis (hazard ratio [95% confidence interval]: for albumin, 2.13 [1.13-4.0]; for AST, 2.53 [1.06-6.03]; for ALT, 2.4 [1.06-5.44]; all P <0.05). Patients with abnormal albumin as well as those with markedly elevated AST and ALT had significantly higher mortality compared with patients without these abnormalities: 29% vs. 15%, 39% vs. 19%, and 38% vs. 19%, respectively; all P <0.05. (FIGuRE 2AbC) . A multivariable Cox model of LFTs (adjusted for age, NT-proBNP, and creatinine / estimated glomerular filtration rate [eGFR] ) revealed that markedly elevated ALT and low albumin were significant prognosticators of adverse outcome (TAbLE 4) . statistical analysis Continuous variables with normal distribution were described using means ± standard deviation; variables with skewed distribution were described by medians with upper and lower quartiles; categorized variables were presented as numbers and percentage. Variables with skewed distribution were normalized by a logarithm. The statistical significance of differences between the groups were assessed using t test, Mann-Whitney U test, or χ 2 test, where appropriate.
Survival analyses were made using Cox proportional univariate hazard models, and the Kaplan--Meier survival curves were demonstrated.
The associations between clinical/laboratory variables (age, sex, etiology of heart failure, systolic blood pressure on admission, hemoglobin, Na + , creatinine, BUN, LFTs, NT-proBNP, pH, serum osmolarity, lactate, LVEF, LVEDD, and RVEDD) and abnormal LFTs were assessed by univariate logistic regression analyses. All variables that were significantly associated with abnormal LFTs in a univariate model were used to build a multivariate model.
The relationships between variables were assessed using the Spearman rank coefficients. A P-value below 0.05 was considered statistically significant. dl, and 3.8 [3.5; 4 .1] mg/dl, respectively. Abnormal LFTs were common in the study population, with the prevalence of 46% for AST, 31% for ALT, 33% for bilirubin, and 44% for albumin (FIGuRE 1). Only 54 patients (29%) had all LFTs within the normal range.
The percentage of patients with elevated baseline bilirubin was higher in patients with decompensated CHF compared with de novo AHF (52% vs. 26%, P <0.01) (FIGuRE 1). We did not find any difference in the prevalence of other abnormal LFTs between decompensated CHF and de novo AHF. We found strong correlations between bilirubin and mean PAP (r = 0.49) and RAP (r = 0.59) (both P <0.05).
A multivariable regression analysis revealed that RAP was independently associated with elevated bilirubin (P <0.005) (FIGuRE 3 ). There were no correlations between AST, ALT, albumin, and hemodynamic parameters.
dIsCussION Several laboratory tests to asses liver function are available, each providing different clinical information. Among them, AST and ALT, bilirubin, and albumin are often used.
Relationship between hemodynamic indices and liver function tests Based on clinical indications, 21 patients (11%) underwent hemodynamic assessment. There were no differences in the hemodynamic profile of patients with normal vs. elevated transaminases. Patients with elevated bilirubin when compared with patients with normal bilirubin had lower CI (2.0 ±0.3 vs. 2.4 ±0.6 l/min), higher RAP (13 ±6 vs. 5 ±3 mmHg), and mean PAP (38 ±11 vs. 27 ±11 mmHg) (all P <0.05) ( (21) 25 (19) 30 (51) 8 (14) 23 (39) 74 (59) 26 (21) 25 (20) comorbidities myocardial infarction hypertension atrial fibrillation diabetes 49 (38) 82 (63) 57 (44) 56 (43) 15 (25) 28 (47) 33 (56) 41 (69) 49 (39) 77 (61) 58 (46) 57 (45) medications (before hospitalization)
ACEI/ARB β-blockers aldosterone antagonists diuretics digoxin VKA/ASA 84 (65) 88 (68) 51 (39) 96 (74) 29 (22) 82 (63) 42 (71) 42 (71) 27 (46) 44 (75) 13 (22) 38 (64) 88 (70) 89 (71) 54 (43) 99 (79) 30 (24) 84 (67) liver function tests Data are shown as number (%), mean ± SD, or median (IQR).
a P <0.05, b P <0.01, c P <0.001
Abbreviations: MAP -mean arterial pressure, PAP -pulmonary artery pressure, PCWP -pulmonary capillary wedge pressure, RAP -right atrial pressure, others -see TAbLE 1 significance of abnormalities of each LFT in AHF remain limited.
10,12
Our study shows that abnormal LFTs are common in AHF, with 71% of the patients having at least 1 abnormal test on admission. To the best of our knowledge, this is the first report on the prevalence of abnormal LFTs in contemporary broad spectrum of patients with AHF. Previous papers described this problem in selected subgroups of patients, e.g., the paper by Shinagawa et al.
13 in decompensated patients with the ejection fraction below 40%. 13 The most (30) 33 (52) 9 (14) 23 (37) 59 (57) 26 (25) 18 (17) 48 ( (65) 18 (17) 17 (19) 39 (46) 17 (20) 25 (34) 15 (24) a 33 (52) 32 (51) 20 (32) 36 (35) 69 (67) 47 (46) 44 (43) 28 (33) 41 (48) a 43 (50) 33 (38) 41 (42) 67 (68) 49 (50) 46 (47) 23 (28) 42 (52) 41 (51) 31 (38) 38 (60) 41 (65) 24 (38) 38 (60) b 12 (19) 36 (57) 63 (61) 62 (60) 27 (26) 65 (63) 13 (13) 60 (58) 63 (73) 68 (79) (70) 78 (74) 75 (72) 46 (44) 79 (75) 20 (19) 70 (67) 48 (57) 55 (65) 32 (38) 61 (73) 22 (26) 50 (59) 58 ( Elevated transaminases are sensitive markers of liver injury, elevated bilirubin usually indicates cholestasis or extensive heme breakdown, and low albumin reflects impaired liver synthetic capabilities. It is worth noting that the magnitude of transaminases' elevation in different pathologic conditions vary dramatically and the cutoffs for clinical significance are usually arbitrary. We assumed that AST and ALT exceeding 3 times the upper normal limit will define marked alteration of transaminases. Surprisingly, the data on the prevalence, pathophysiology, and clinical Somehow unexpectedly, we found that abnormal LFTs (all but albumin) were associated with high hemoglobin levels. It is surprising since anemia is a well-established, independent factor of unfavorable outcome in heart failure.
14,15 High hemoglobin may be a marker of low fluid status (hemoconcentration), which subsequently may lead to hypoperfusion and liver cell dysfunction/ damage. This pathomechanism may at least in part explain our findings. However, abnormal LFTs were also associated with elevated NT-proBNP -a marker of fluid overload, which shows that pathophysiology of the phenomenon is more complex and needs to be further studied.
Our data support the hypothesis that liver dysfunction may have adverse effect on prognosis in AHF patients. Interestingly, unlike other authors, we did not observe higher mortality in patients with elevated bilirubin. 10, 13, 16 It has already been demonstrated that in CHF bilirubin is independently associated with morbidity and mortality. 3 In a nontrial population of more than 16,500 CHF patients, Yu et al. 5 observed that low albumin and elevated bilirubin were risk factors of total mortality. Batin et al. 16 has also demonstrated that AST along with bilirubin have prognostic importance in CHF patients. 16 Shinagawa et al. 12, 13 studied clinical implications of liver dysfunction in AHF and found elevated total bilirubin on admission to be a marker of poor prognosis. 12,13 Only recently, Ambrosy et al.
10 identified high bilirubin and low albumin, but not elevated ALT, to have prognostic importance in AHF. The discrepancy with our findings may be explained by the fact that they analyzed the population of selected patients participating in the clinical trial. It may not accurately reflect liver dysfunction across the whole spectrum of AHF patients (the prevalence of abnormal LFTs was lower than in our study). Additionally, they presented mortality analysis with longer follow-up, and such prognosticators may be different than ours.
We have demonstrated that patients with markedly elevated transaminases as well as those with low albumin concentration have significantly higher mortality at 180 days. It is worth noting that albumin concentration may not only reflect liver function itself but also may be a marker of hemodilution due to fluid overload and the patient's nutritional status. This is in line with our finding that low albumin was independently predicted by elevated NT-proBNP levels.
With as few as 40 events at 180 days of follow--up, we were restricted to perform multivariable analyses taking into account only 4 variables. After adjustment for age, NT-proBNP (reflecting severity of AHF and being a well-established prognosticator) and creatinine/eGFR (renal function), we found that markedly elevated ALT and low albumin remained significant prognosticators of adverse outcome. Replacing NT-proBNP with LVEF in the model did not affect the results.
Recent hemodynamic studies have demonstrated that both elevated RAP and decreased CI results recent analysis of the EVEREST trial showed that the percentage of patients with abnormal LFTs varies from 17% for albumin to 62% for γ-glutamyltranspeptidase. 10 In CHF, the prevalence of abnormal LFTs differs between the authors, ranging from 10% to 40%.
3,5,9,10 Based on our data, we can conclude that the prevalence of LFT abnormalities in contemporary population with AHF is higher than that reported in clinical trials and that described in CHF patients. The latter phenomenon may indicate that liver dysfunction is a part of AHF pathophysiology. Our data also shows that patients with acutely decompensated CHF have higher prevalence of abnormal bilirubin, but not transaminases and albumin, when compared with de novo AHF. We can speculate that the difference may reflect the different intensity of pathophysiological processes that lead to liver dysfunction in heart failure (acutely decompensated chronic compared with de novo).
As the pathophysiology of the liver dysfunction in heart failure is not completely understood, one may speculate that some of the processes that lead to the development of cardiorenal syndrome may also influence bilateral cardiohepatic interactions.
2 However, our data do not support this hypothesis. Abnormal LFTs were not associated with kidney function tests; moreover, patients with abnormal LFTs were not characterized by worse kidney function when compared with patients with normal LFTs (only patients with elevated bilirubin had higher BUN but not creatinine). This can be explained by the fact that the liver, unlike the kidneys, has dual (portal vein and hepatic artery) blood supply, which should make this organ more resistant to decreased cardiac output and low perfusion state. Abbreviations: CI -confidence interval, NA -sodium, NS -nonsignificant, RVEDDright ventricular end-diastolic diameter, others -see TAbLE 1 extend these findings to acute conditions. We observed a strong effect of deteriorated hemodynamics on bilirubin and a weak effect on other LFTs. Patients with elevated bilirubin had lower CI and higher pressures in the right side of the heart (RAP, PAP) and tended for higher PCWP. We observed a strong correlation between RAP and bilirubin, in the elevation of both transaminases and total bilirubin, 9,12,17 whereas reduced CI alone leads to an increase in AST, ALT and direct but not total bilirubin. 9 Thus, both hypoperfusion and congestion play an important role in the development of liver dysfunction in heart failure. Since most of these studies were performed in CHF, our data indicating that bilirubin may be a marker of venous pressure and tissue congestion. It is worth noting that since invasive hemodynamic monitoring is not a part of routine AHF patient assessment, it was performed only in 21 patients in whom it was judged as clinically mandatory. A limitation of our study is the small and selected subpopulation of patients who underwent right heart catheterization.
In conclusion, abnormal LFTs are common in AHF and may identify patients with worse outcome. Elevated bilirubin is strongly correlated with RAP indicating that congestion is an important process leading to hyperbilirubinemia in AHF; however, further investigations are needed. 
